Literature DB >> 21827757

MicroRNA-451 regulates p38 MAPK signaling by targeting of Ywhaz and suppresses the mesangial hypertrophy in early diabetic nephropathy.

Zheng Zhang1, Xiaomei Luo, Songtao Ding, Junxia Chen, Tao Chen, Xin Chen, He Zha, Li Yao, Xiaoyan He, Huimin Peng.   

Abstract

Diabetic nephropathy (DN) is a major diabetic complication. However, the initiating molecular events triggering DN are unknown. In this study we focused on microRNA-451 (miR-451), which is downregulated during early DN. We found that miR-451 negatively regulated the expression of Ywhaz through Ywhaz 3'UTR and that Ywhaz was required for the miR-451-mediated downregulation of p38 MAPK signalling. Moreover, over-expression of miR-451 inhibits glomerular mesangial cell proliferation in vitro and in vivo. These findings suggest that the growth-inhibitory effect of miR-451 may be explained in part by miR-451-induced suppression of Ywhaz and p38 MAPK signalling, providing evidence for the potential role of miR-451 in early DN.
Copyright © 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21827757     DOI: 10.1016/j.febslet.2011.07.042

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  41 in total

Review 1.  Anti-fibrosis therapy and diabetic nephropathy.

Authors:  Anil Karihaloo
Journal:  Curr Diab Rep       Date:  2012-08       Impact factor: 4.810

2.  MiR-451 suppresses cell proliferation and metastasis in A549 lung cancer cells.

Authors:  Pin Yin; Rui Peng; Huimin Peng; Li Yao; Yan Sun; Li Wen; Tianhui Wu; Ji Zhou; Zheng Zhang
Journal:  Mol Biotechnol       Date:  2015-01       Impact factor: 2.695

Review 3.  MicroRNAs in diabetic nephropathy: functions, biomarkers, and therapeutic targets.

Authors:  Mitsuo Kato; Rama Natarajan
Journal:  Ann N Y Acad Sci       Date:  2015-04-15       Impact factor: 5.691

4.  Decreased secretion and profibrotic activity of tubular exosomes in diabetic kidney disease.

Authors:  Jin Wen; Zhengwei Ma; Man J Livingston; Wei Zhang; Yanggang Yuan; Chunyuan Guo; Yutao Liu; Ping Fu; Zheng Dong
Journal:  Am J Physiol Renal Physiol       Date:  2020-07-27

5.  Systemic inhibition of miR-451 increases fibrotic signaling and diminishes autophagic response to exacerbate renal damage in Tallyho/Jng mice.

Authors:  Maurice B Fluitt; Narayan Shivapurkar; Manju Kumari; Sarojini Singh; Lijun Li; Swasti Tiwari; Carolyn M Ecelbarger
Journal:  Am J Physiol Renal Physiol       Date:  2020-07-27

6.  Down-regulation of miR-34a alleviates mesangial proliferation in vitro and glomerular hypertrophy in early diabetic nephropathy mice by targeting GAS1.

Authors:  Le Zhang; Siyi He; Shaodong Guo; Wei Xie; Rong Xin; Hua Yu; Fan Yang; Jing Qiu; Di Zhang; Shiwen Zhou; Kebin Zhang
Journal:  J Diabetes Complications       Date:  2014-01-11       Impact factor: 2.852

Review 7.  Emerging roles for miRNAs in the development, diagnosis, and treatment of diabetic nephropathy.

Authors:  Johanna K DiStefano; Matthew Taila; M Lucrecia Alvarez
Journal:  Curr Diab Rep       Date:  2013-08       Impact factor: 4.810

Review 8.  MicroRNAs as novel therapeutic targets to treat kidney injury and fibrosis.

Authors:  Ivan G Gomez; Naoki Nakagawa; Jeremy S Duffield
Journal:  Am J Physiol Renal Physiol       Date:  2016-02-24

9.  Directly visualized glioblastoma-derived extracellular vesicles transfer RNA to microglia/macrophages in the brain.

Authors:  Kristan E van der Vos; Erik R Abels; Xuan Zhang; Charles Lai; Esteban Carrizosa; Derek Oakley; Shilpa Prabhakar; Osama Mardini; Matheus H W Crommentuijn; Johan Skog; Anna M Krichevsky; Anat Stemmer-Rachamimov; Thorsten R Mempel; Joseph El Khoury; Suzanne E Hickman; Xandra O Breakefield
Journal:  Neuro Oncol       Date:  2015-10-03       Impact factor: 12.300

Review 10.  Early detection of diabetic kidney disease: Present limitations and future perspectives.

Authors:  Chih-Hung Lin; Yi-Cheng Chang; Lee-Ming Chuang
Journal:  World J Diabetes       Date:  2016-07-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.